BAFNA PHARMACEUTICALS LTD (BAFNAPH) financials

BAFNA PHARMACEUTICALS LTD (BAFNAPH) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1981, Bafna PharmaceuticalsLtd manufactures finished pharmaceutical formulations[1]

Market Cap: ₹1,091Cr.
Current Price: ₹461
Stock P/E: 140
ROE: 12.3%
ROCE: 11.9%
Book Value: ₹40.6
Dividend Yield: 0.00%
52W High / Low: ₹469/94.8

In Jun 2026, BAFNA PHARMACEUTICALS LTD (BAFNAPH) reported sales ₹26.58 Cr and net profit ₹0.08 Cr.

Annual TTM: sales ₹143 Cr, net profit ₹8 Cr.

Shareholding: Promoters 75.00% (Jun 2026), FIIs 9.34% (Jun 2026), Public 15.66% (Jun 2026), No. of Shareholders 7,062% (Jun 2026).

BAFNAPH quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	40.32	33.19	39.06	34.62	35.47	38.29	42.24	26.58
Expenses	36.53	30.13	35.95	29.55	31.19	35.24	38.69	25.69
Operating Profit	3.79	3.06	3.11	5.07	4.28	3.05	3.55	0.89
OPM %	9.40%	9.22%	7.96%	14.64%	12.07%	7.97%	8.40%	3.35%
Other Income	1.02	0.18	-0.76	0.60	1.18	1.22	1.76	1.91
Interest	0.62	0.64	0.82	0.91	0.86	0.86	1.03	0.94
Depreciation	1.58	1.66	0.22	1.37	1.47	1.57	1.66	1.78
Profit before tax	2.61	0.94	1.31	3.39	3.13	1.84	2.62	0.08
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.96%	0.00%
Net Profit	2.62	0.95	1.31	3.39	3.12	1.84	2.75	0.08
EPS in Rs	1.11	0.40	0.55	1.43	1.32	0.78	1.16	0.03
Raw PDF	—	—	—	—	—	—	—	—

BAFNAPH profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	42	71	85	115	152	146	151	143
Expenses	41	61	73	100	141	135	135	131
Operating Profit	1	10	12	16	11	11	16	12
OPM %	2.9%	14%	14%	14%	7%	8%	11%	8%
Other Income	-23	1	-0	3	4	1	5	6
Interest	0	1	1	2	2	3	4	4
Depreciation	3	4	5	5	5	5	6	6
Profit before tax	-25	6	5	12	7	4	11	8
Tax %	0%	0%	0%	2%	0%	0%	-1%	—
Net Profit	-25	6	5	11	7	4	11	8
EPS in Rs	-106.53	2.46	2.21	4.79	3.11	1.75	4.69	3.29
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

BAFNAPH balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24	2	24	24	24	24	24	24
Reserves	-3	49	33	38	50	57	61	72
Borrowings	46	3	15	11	23	24	28	37
Other Liabilities	54	17	14	17	33	42	40	42
Total Liabilities	121	71	86	90	130	148	153	176
Fixed Assets	37	35	36	39	40	40	59	82
CWIP	0	0	1	0	2	12	7	3
Investments	1	0	0	0	0	0	0	0
Other Assets	82	36	50	51	88	95	87	91
Total Assets	121	71	86	90	130	148	153	176

BAFNAPH cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-1	-34	-14	10	5	9	22	15
Cash from Investing Activity	4	33	-5	-7	-7	-15	-21	-22
Cash from Financing Activity	-2	7	12	-5	10	-1	1	6
Net Cash Flow	0	6	-7	-2	8	-6	2	-1
Free Cash Flow	-1	-36	-20	2	-2	-6	0	-10
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	8%	-2,786%	-132%	83%	32%	87%	194%	94%

BAFNAPH shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	88.29%	88.29%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
FIIs	0.00%	0.00%	8.53%	9.34%	9.34%	9.34%	9.34%	9.34%
Public	11.70%	11.70%	16.47%	15.66%	15.66%	15.66%	15.66%	15.66%
No. of Shareholders	7,295	7,214	7,142	7,283	7,572	7,119	6,928	7,062

BAFNAPH key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	208	52	49	63	130	109	101	106
Inventory Days	122	208	154	185	129	125	127	129
Days Payable	517	229	107	113	165	149	140	139
Cash Conversion Cycle	-188	31	96	135	94	84	88	96
Working Capital Days	-210	89	121	123	104	92	74	74
ROCE %	-21%	-3%	10%	11%	16%	9%	8%	12%

BAFNAPHUpdated 18 Oct 2026, 17:36

Bafna Pharmaceuticals Ltd

BAFNAPHUpdated 18 Oct 2026, 17:36

Market Cap

₹1,091Cr.

Current Price

₹461

High / Low

₹469/94.8

Stock P/E

140

ROE12.3%

ROCE11.9%

Book Value₹40.6

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 1981, Bafna PharmaceuticalsLtd manufactures finished pharmaceutical formulations[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	41.95	0.6	35.66	1.87	1.21	6.35	0	6.35	2.68
Sep 2023	40.68	0.44	36.67	0.16	1.24	2.49	0	2.48	1.05
Dec 2023	28.44	0.58	30.51	0.98	1.27	-2.94	0	-2.94	-1.24
Mar 2024	41.4	0.68	38.51	0.52	1.27	1.46	0	1.46	0.62
Jun 2024	33.29	0.65	32.08	0.16	1.44	-0.72	0	-0.72	-0.3
Sep 2024	40.32	0.62	36.53	1.02	1.58	2.61	0	2.62	1.11
Dec 2024	33.19	0.64	30.13	0.18	1.66	0.94	0	0.95	0.4
Mar 2025	39.06	0.82	35.95	-0.76	0.22	1.31	0	1.31	0.55
Jun 2025	34.62	0.91	29.55	0.6	1.37	3.39	0	3.39	1.43
Sep 2025	35.47	0.86	31.19	1.18	1.47	3.13	0	3.12	1.32
Dec 2025	38.29	0.86	35.24	1.22	1.57	1.84	0	1.84	0.78
Mar 2026	42.24	1.03	38.69	1.76	1.66	2.62	-4.96	2.75	1.16
Jun 2026	26.58	0.94	25.69	1.91	1.78	0.08	0	0.08	0.03

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	100	12	116	40	5	6	0	6	3.28
Mar 2016	85	12	82	1	4	-13	-3	-12	-6.53
Mar 2017	65	11	70	1	4	-19	-4	-18	-9.9
Mar 2018	46	7	81	31	4	-14	15	-16	-6.95
Mar 2019	44	2	57	0	3	-18	8	-20	-8.34
Mar 2020	42	0	41	-23	3	-25	0	-25	-106.53
Mar 2021	71	1	61	1	4	6	0	6	2.46
Mar 2022	85	1	73	0	5	5	0	5	2.21
Mar 2023	115	2	100	3	5	12	2	11	4.79
Mar 2024	152	2	141	4	5	7	0	7	3.11
Mar 2025	146	3	135	1	5	4	0	4	1.75
Mar 2026	151	4	135	5	6	11	-1	11	4.69
TTM	143	4	131	6	6	8	—	8	3.29

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	75%
FIIs	9.34%
Public	15.66%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	88.73%	0%	—	11.27%
Dec 2023	88.42%	0%	—	11.57%
Mar 2024	88.29%	0%	—	11.7%
Jun 2024	88.29%	0%	—	11.71%
Sep 2024	88.29%	0%	—	11.7%
Dec 2024	88.29%	0%	—	11.7%
Mar 2025	75%	8.53%	—	16.47%
Jun 2025	75%	9.34%	—	15.66%
Sep 2025	75%	9.34%	—	15.66%
Dec 2025	75%	9.34%	—	15.66%
Mar 2026	75%	9.34%	—	15.66%
Jun 2026	75%	9.34%	—	15.66%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	19	53	64	50	185	49	0	18	118	185
Mar 2016	19	41	80	45	185	47	0	18	120	185
Mar 2017	19	26	82	40	167	43	0	18	106	167
Mar 2018	24	17	47	40	128	40	0	1	86	128
Mar 2019	24	-3	46	54	121	37	0	1	82	121
Mar 2020	2	49	3	17	71	35	0	0	36	71
Mar 2021	24	33	15	14	86	36	1	0	50	86
Mar 2022	24	38	11	17	90	39	0	0	51	90
Mar 2023	24	50	23	33	130	40	2	0	88	130
Mar 2024	24	57	24	42	148	40	12	0	95	148
Mar 2025	24	61	28	40	153	59	7	0	87	153
Mar 2026	24	72	37	42	176	82	3	0	91	176

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	9	56	-66	0
Mar 2016	-3	-1	4	0
Mar 2017	14	-8	-5	0
Mar 2018	-7	38	-31	0
Mar 2019	-1	4	-2	0
Mar 2020	-34	33	7	6
Mar 2021	-14	-5	12	-7
Mar 2022	10	-7	-5	-2
Mar 2023	5	-7	10	8
Mar 2024	9	-15	-1	-6
Mar 2025	22	-21	1	2
Mar 2026	15	-22	6	-1

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	303	291	302	195	208	52	49	63	130	109	101	106
Inventory Days	66	92	118	102	122	208	154	185	129	125	127	129
Days Payable	149	169	164	265	517	229	107	113	165	149	140	139
Cash Conversion Cycle	220	214	255	31	-188	31	96	135	94	84	88	96
Working Capital Days	56	125	-36	-108	-210	89	121	123	104	92	74	74
ROCE %	-13%	-0%	-6%	-35%	-21%	-3%	10%	11%	16%	9%	8%	12%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BAFNA PHARMACEUTICALS LTD (BAFNAPH)?

The reported market capitalisation for BAFNA PHARMACEUTICALS LTD (BAFNAPH) is ₹1,091Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BAFNAPH?

The current price shown for BAFNA PHARMACEUTICALS LTD (BAFNAPH) on Fincrux is ₹461 with a 52-week high/low of ₹469/94.8.

What is the P/E ratio of BAFNA PHARMACEUTICALS LTD (BAFNAPH)?

The stock P/E for BAFNA PHARMACEUTICALS LTD (BAFNAPH) is 140 on Fincrux, with ROE at 12.3% and ROCE at 11.9%.

What were BAFNAPH latest quarterly results?

For Jun 2026, BAFNA PHARMACEUTICALS LTD (BAFNAPH) reported sales ₹26.58 Cr and net profit ₹0.08 Cr (figures in ₹ crore unless noted).

What are BAFNAPH annual sales and net profit?

For TTM, BAFNA PHARMACEUTICALS LTD (BAFNAPH) shows sales of ₹143 Cr and net profit of ₹8 Cr on the Fincrux profit & loss statement.

Who owns BAFNA PHARMACEUTICALS LTD (BAFNAPH)?

Latest shareholding for BAFNA PHARMACEUTICALS LTD (BAFNAPH) on Fincrux: Promoters 75.00% (Jun 2026), FIIs 9.34% (Jun 2026), Public 15.66% (Jun 2026), No. of Shareholders 7,062% (Jun 2026).

Where can I find BAFNA PHARMACEUTICALS LTD (BAFNAPH) financials?

BAFNA PHARMACEUTICALS LTD (BAFNAPH) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BAFNAPH balance sheet and cash flow?

Yes. The BAFNA PHARMACEUTICALS LTD (BAFNAPH) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 17:36